A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

Also called NCT07799688

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07799688
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07799688. Randomized; no masking; primary purpose treatment. Start 2026-09-11 (actual); primary completion 2028-10-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia
Condition
Hyperlipidemia
Intervention (Drug)
HRS-7249 Injection
Intervention (Drug)
HRS-7249 Injection
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07799688
Content hash
a8e379441306cf4c0341135345d4097a21f0731efb6b2ef4ca598580b147df74